Sinopharm, a state-controlled company, said its candidate had a 79 percent efficacy rate in interim late-stage trials. But crucial questions remained unanswered.
Sinopharm, a state-controlled company, said its candidate had a 79 percent efficacy rate in interim late-stage trials. But crucial questions remained unanswered.